Therapeutic area intelligence for Oncolytic Virus Therapy with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

nivolumab →

Phase →

Tudriqev →

Recent signals(3)

RegulatoryAugust 7, 2026

FDA Grants Accelerated Approval for Tudriqev in Advanced Melanoma

The FDA has approved Tudriqev, a genetically modified oncolytic viral therapy, for treatment-resistant advanced melanoma.

RegulatoryAugust 7, 2026

FDA grants accelerated approval to vusolimogene oderparepvec-wtpg with nivolumab for melanoma

The FDA has granted accelerated approval for vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma.

ClinicalJuly 9, 2026

Phase I Trial of Adze1.C in Advanced Melanoma Shows Promise

A Phase I clinical trial is underway to evaluate the safety and preliminary efficacy of Adze1.C in patients with metastatic melanoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.